ProCE Banner Activity

What Everyone Should Know About Management of Advanced EGFR-Mutated Non-Small-Cell Lung Cancer in 2021

Clinical Thought
Get up to date on current best practices in the treatment of metastatic NSCLC with actionable EGFR mutations, including expert advice on biomarker testing, therapy selection for newly diagnosed and progressive disease, and managing adverse events with EGFR inhibition.

Released: March 08, 2021

Expiration: March 07, 2022

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received funds for research support paid to his institution from Celgene, Merck, Novartis, OncoMed, and Roche and consulting fees from AstraZeneca, Beyond Spring, Boehringer Ingelheim, Bristol-Myers Squibb, Inivata, and Takeda.